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ABSTRACT
Objective To determine for how long after a first
unprovoked seizure a driver must be seizure-free before
the risk of recurrence in the next 12 months falls below
20%, enabling them to regain their driving licence.
Design Randomised controlled trial: Multicentre study of
early Epilepsy and Single Seizures (MESS).
Setting UK hospital outpatient clinics from 1 January
1993 to 31 December 2000.
Participants People entered MESS if they had had one or
more unprovoked seizures and both the participant and
the clinician were uncertain about the need to start
antiepileptic drug treatment. The subset of people used
for this analysis comprised participants aged at least
16 years with a single unprovoked seizure.
Main outcome measure Risk of seizure recurrence in the
12 months after a seizure-free period of 6, 12, 18, or
24 months from the date of the first (index) seizure.
Regression modelling was used to investigate how
antiepileptic treatment and several clinical factors
influence the risk of seizure recurrence.
Results At six months after the index seizure the risk of
recurrence in the next 12 months for those who start
antiepileptic drugs was significantly below 20%
(unadjusted risk 14%, 95% confidence interval 10% to
18%). For patients who did not start treatment the risk
estimate was less than 20% but the upper limit of the
confidence interval was greater than 20% (18%, 13% to
23%). Multivariable analyses identified subgroups with a
significantlygreaterthan20%riskofseizurerecurrencein
the 12 months after a six month seizure-free period, such
as those with a remote symptomatic seizure with
abnormal electroencephalogram results.
Conclusion After a single unprovoked seizure this
reanalysis of MESS provides estimates of seizure
recurrence risks that will inform policy and guidance
about regaining an ordinary driving licence. Further
guidance is needed as to how such data should be
utilised; in particular, whether a population approach
shouldbetaken withafocusontheunadjustedresultsor
whether attempts should be made to individualise risk.
Guidance is also required as to whether the focus should
be on risk estimates only or on the confidence interval as
well. If the focus is on the estimate only our unadjusted
estimatessuggestthattreatedanduntreatedpatientsare
eligible to drive after being seizure-free for six months. If
the focus is also on confidence intervals, direction is
needed as to whether a conservative or liberal approach
should be taken.
Trial registration Current Controlled Trials
ISRCTN98767960.
INTRODUCTION
Driving regulations in the European Union currently
differ among member states.
1 In 1995 and 1996 the
International League Against Epilepsy and the Inter-
national Bureau for Epilepsy organised workshops to
discuss driving regulations around epilepsy and sei-
zures, but the recommendations were never reflected
in an official European guideline or in European law.
Following further calls for harmonisation across the
EuropeanUnion,
2-4 memberstateshavebeen engaged
inaprocessofidentifyingminimumstandardsfordriv-
ing, and these are now in the process of being imple-
mented in the United Kingdom and other European
Union states. Where possible the United Kingdom
based Driving and Vehicle Licensing Agency adopt a
risk based approach to determine who can return to
driving after an incapacitating event such as an epilep-
ticseizure.
5Epilepsycomesunderthe1988RoadTraf-
fic Act, but single seizures, which by definition do not
constitute epilepsy, come under the domestic regula-
tions(1999MotorVehicles(DrivingLicences)Regula-
tions). People who have had a single unprovoked
seizure are usually allowed to regain their ordinary
(group 1) driving licence six months after the event
provided their risk of a seizure recurrence in the next
year is below 20%. Drivers can regain their heavy
goods vehicle (group 2) licence after five years pro-
vided their risk of a recurrence is below 2% and they
have not been taking antiepileptic drugs for five years.
Althoughtheseminimumrisklevelsof20%and2%are
somewhatarbitrary,theyaresupportedbyothermem-
ber states
4 and have been adopted in the criteria deter-
mining minimum driving standards that are being
harmonised across the European Union. We are not
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that have such a risk based approach. In the United
States each individual state has its own legislation for
driving with epilepsy and seizures. When surveyed in
2001
6moststates(n=28)requiredpeoplewithepilepsy
tohaveatimeoffdriving(mediansixmonths),whereas
in19statesthe timewasdecidedbythe treatingdoctor
or a medical advisory board.
When implementing the new European Union leg-
islation, member states may adopt the minimum stan-
dard and should not allow a more lenient standard.
Member states can, however, adopt a stricter standard
provideditcanbejustified,althoughitislikelythatany
state that sets a more stringent standard would face a
challenge in court. In October 2009, after a discussion
at a meeting of the Driving and Vehicle Licensing
Agency’s neurology panel, at which the findings in
this paper were also discussed, the agency altered its
guidance.
5Itstatedthatafterafirstunprovokedseizure
drivers could regain their ordinary licence once they
had been seizure-free for six months provided that
their risk of a recurrence over the next year was
belowthis20%cut-off.Fewpublishedstudieshaveesti-
mated the risk of seizure recurrence and investigated
factors that modify risk. Publications that do exist
78
have focused on recurrence immediately after a first
seizure and none have presented risks of recurrence
in the next 12 months at time points such as six or
12 months after an index seizure. Reliable published
dataarethereforeneededtoinformdecisionsmadeby
clinicians, Driving and Vehicle Licensing Agency gui-
dance or European Union legislation, and legislation
outside the European Union.
The Multicentre study of early Epilepsy and Single
Seizures (MESS)
9 was a randomised controlled trial
that compared the policies of immediate or deferred
treatment in peoplepresenting with a first unprovoked
seizureorwithearlyepilepsy.Thetrialremainsthelar-
gest reported study of patients with single seizures and
earlyepilepsy,andalthoughtheprimarypurposeofthe
study was to compare treatment policies, it also pro-
vided an important opportunity to examine the risks
of seizure recurrence and factors that modify those
risks. Outcomes assessed included time to seizure
recurrence, time to two year remission, and quality of
life. In this paper we analysed data from participants
with only a single unprovoked seizure, referred to as
the index seizure, at entry into the MESS study to esti-
mate seizure recurrence risk in the 12 months after the
index seizure. We used modelling to investigate how
antiepilepticdrugtreatmentandseveralclinicalfactors
influence the risk of seizure recurrence.
METHODS
ThemethodsfortheMESSstudyhavebeenpublished
elsewhere.
9 Briefly, patients were eligible for inclusion
iftheywereatleastonemonthold;hadhadatleastone
clinically definite, spontaneous, unprovoked epileptic
seizure; and if both the clinician and the patient (or
carer)wereuncertainaboutwhetherornottostartanti-
epileptic drugs. Exclusion criteria included previous
treatment with antiepileptic drugs or the presence of a
progressive neurological disease. People were
recruited to the trial between 1 January 1993 and 31
December 2000 and were followed up, if possible,
from 31 December 2001 to 30 June 2002. After the
recruiting doctor had obtained informed consent and
enrolled the participant, participants were allocated
randomly to treatment policy by phone or fax by way
of the minimisation method, which was balanced
across centre or region and number of seizures at ran-
domisation. For participants assigned to immediate
treatment, the clinician selected the optimum anti-
epileptic drug, based on their usual practice, and
started treatment as early as possible. Participants
assigned to deferred treatment received no drugs
until the clinician and patient agreed that it was neces-
sary, mainly after a seizure recurrence.
Table 1 |Characteristics of patients. Values are numbers (percentages) unless stated
otherwise
Characteristic
Immediate treatment
(n=317)
Delayed treatment
(n=320)
Total
(n=637)
Median (interquartile range) age
at randomisation (years)
32.0 (21.5-49.5) 33.8 (22.4-50.6) 32.9 (21.9-50.3)
Male 199 (63) 213 (67) 412 (645)
Female 118 (37) 107 (33) 225 (35)
Cause of seizure:
Remote symptomatic 55 (17) 49 (15) 104 (16)
Not remote symptomatic 262 (83) 271 (85) 533 (84)
Neurological deficit:
Absent 288 (91) 299 (94) 587 (92)
Present 27 (8) 19 (5) 46 (7)
Missing 2 (1) 2 (1) 4 (1)
Previousacute symptomatic seizures:
Febrile 15 (5) 14 (4) 29 (5)
Other 1 (0) 7 (2) 8 (1)
None 301 (95) 299 (94) 600 (94)
Epilepsy in first degree relative:
Yes 33 (10) 34 (11) 67 (10)
No 284 (90) 286 (89) 570 (90)
Seizures:
Partial 102 (32) 100 (31) 202 (32)
Generalised or not definitely partial 205 (65) 217 (68) 422 (66)
Other 10 (3) 3 (1) 13 (2)
Seizures only while asleep:
Yes 65 (20) 50 (16) 115 (18)
No 252 (80) 269 (84) 521 (82)
Missing - 1 (0) 1 (0)
EEG results:
Normal 147 (46) 136 (43) 283 (44)
Abnormal 149 (47) 160 (50) 309 (49)
Not done or missing 21 (7) 24 (7) 45 (7)
CT or MRI scan results:
Normal 219 (69) 231 (72) 450 (71)
Abnormal 38 (12) 34 (11) 72 (11)
Not done or missing 60 (19) 55 (17) 115 (18)
EEG=electroencephalogram; CT=computed tomography; MRI=magnetic resonance imaging.
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graphic data for all randomised participants and those
eligible people who did not provide consent for rando-
misation.Electroencephalographywasrequestedforall
randomisedparticipants,andbrainimaging(computed
tomography or magnetic resonance imaging) was
undertaken if clinically indicated. Follow-up occurred
atthree,six,and12monthsandsuccessiveyearlyinter-
vals from randomisation, with additional visits as clini-
callyindicated.At each visit the occurrence andtypeof
seizure was recorded, together with antiepileptic drugs
and any adverse events.
In the original MESS study outcomes were time
fromrandomisationtofirstseizure,tofirsttonic-clonic
seizure, and to second and fifth seizure; time to two
year remission; the proportion of patients seizure-free
for two years between one and three years afterrando-
misation and three and five years after randomisation;
adverse events; and quality of life. To make the analy-
sis reported here relevant to those of driving age, we
included participants with a single seizure only and
aged 16 years or over. We chose 16 as the lower cut-
off as by age 17, after 12 months of follow-up, these
participantswouldbeeligibleforaprovisionallicence.
Patients were classified as remote symptomatic if on
entry to MESS the clinician considered that their sei-
zure was caused by a remote disease or event such as a
head injury; meningitis or encephalitis, or both; intra-
cranial surgery; or other disease. Neurological deficit
included hemiparesis and learning difficulty, and an
abnormal electroencephalogram was defined as epi-
leptiform activity with focal or generalised spikes or
spike and slow wave activity.
Statistical analysis
We restricted our analyses to those aged 16 years or
older with a single seizure on entry into MESS.
AlthoughMESSwasarandomisedtrial,inthisanalysis
we measured time to event from the date of the first
seizure, occurring before study entry, referred to as
the index seizure, and not the date of randomisation.
The outcome of interest was the probability of being
seizure-free for the next 12 months having been sei-
zure-free from the index seizure to the time point in
question. For example, the probability of someone
who was seizure-free for six months after his or her
index seizure, remaining seizure-free for seven to
18 months was calculated by dividing the probability
of being seizure-free for 18 months by the probability
of being seizure-free for six months. We similarly cal-
culated the risks of recurrence in the next 12 months
for other time points, and used a revised version of
Greenwood’s formula to calculate the confidence
intervals for these estimates.
10-12
We determined those variables associated with a
higher risk of seizure recurrence both univariately
and after adjusting for multiple variables using log-
rank tests and Cox proportional hazards modelling
methods. We produced a best fitting, parsimonious,
multivariable model with variable reduction by
Akaike’s information criterion.
13 For this model we
excluded missing values except in the case of results
for electroencephalography and computed tomogra-
phyor magneticresonanceimaging,wherewe created
athirdcategoryformissingornotdone.Fromthemul-
tivariablemodelwecalculatedtheriskofrecurrencein
the next 12 months for combinations of risk factors.
14
RESULTS
Thefigureshowstheflowofpatientsthroughthestudy.
Consent was not obtained for 404 of 1847 eligible
patients. The remaining 1443 patients were rando-
mised; 722 to immediate antiepileptic drug treatment,
of whom 317 had a recorded date of index seizure and
were analysed, and 721 to deferred antiepileptic drug
treatment, of whom 320 were analysed. Table 1 sum-
marises the characteristics of the patients.
In the immediatetreatment group the unadjusted risk
of recurrence in the next 12 months at six months after
theindexseizurewas14%(95%confidenceinterval10%
to 18%), significantly below 20% (table 2). For the
delayed treatment group the estimate was 18% but the
confidence interval (13% to 23%) did not exclude a 20%
risk of recurrence. At 12 months, however, the risk was
reduced to 10% (6% to 15%), significantly below 20%.
Treatment policy was included as a covariate for the
univariate and the multivariable modelling (table 3).
In the univariate model factors significantly associated
with a higher risk of seizure recurrence were a remote
Assessed for eligibility (n=1847)
Randomised to
deferred antiepileptic
drug treatment (n=721)
Randomised to
immediate antiepileptic
drug treatment (n=722)
Had date of index seizure
recorded; analysed (n=320)
Had date of index seizure
recorded; analysed (n=317)
Aged at least 16 years at
randomisation (n=544)
Aged at least 16 years at
randomisation (n=555)
Only one seizure before
randomisation (n=324)
Only one seizure before
randomisation (n=323)
Excluded (no consent; n=404)
Flow of patients through study
Table 2 |Risk of seizure recurrence over 12 months at time points after index seizure: risk (%,
95% confidence interval)
Time after index seizure
(months)
Immediate treatment Delayed treatment
No at risk
Risk of seizure
in next 12 months No at risk
Risk of seizure
in next 12 months
6 260 14 (10 to 18) 254 18 (13 to 23)
12 230 7 (4 to 11) 219 10 (6 to 15)
18 211 8 (5 to 12) 197 12 (8 to 17)
24 199 7 (3 to 10) 182 10 (5 to 14)
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while asleep, abnormal electroencephalogram result,
and absence of computed tomography or magnetic
resonance imaging. Treatment policy was not a signif-
icant factor in the univariate analysis probably owing
to lack of power, as the effect estimate for immediate
treatment is of a similar magnitude to that in the main
analysis of the MESS trial.
Table 4 shows the risk estimates for seizure recur-
rence over 12 months at several time points after the
index seizure based on the univariate analysis for the
variables with significant univariate hazard ratios. At
sixmonthstheestimateforpatientswithaneurological
deficit was above 20%, although the confidence
interval (13% to 49%) did not exclude the possibility
of the risk being below 20%.
In the multivariable analysis (table 3) the parsimo-
niousmodelincludedvariablesforcauseoftheseizure,
epilepsy in a first degree relative, seizure while asleep,
electroencephalogram results, computed tomography
or magnetic resonance imaging scan results, and treat-
ment policy. No evidence suggested that the propor-
tionalhazardsassumption,underlyingtheCoxmodel,
wasinvalid.Fromthe model,remotesymptomaticsei-
zure, seizure while asleep, and an abnormal electroen-
cephalogram result were associated with a higher risk
of seizure recurrence, but again treatment policy was
not a significant factor.
Theriskofrecurrenceat12monthsforpatientswith
particular characteristics was estimated from the parsi-
moniousmultipleregressionmodel.Asalargenumber
of combinations was possible table 5 shows selected
results for remote and non-remote symptomatic sei-
zure, electroencephalogram result, and computed
tomography or magnetic resonance imaging scan
results assuming that the index seizure was not during
sleep and that participants did not have a first degree
relativewithepilepsy.Thetableonbmj.comshowsthe
estimates for all possible combinations of factors.
Although the unadjusted results suggested that
patients who start treatment after a single seizure and
are seizure-free for six months, on average have a less
than 20%risk of recurrencein the next 12 months,our
multivariable results indicated that the risk in some
subgroups was significantly greater than 20%. This
included patients with a remote symptomatic seizure
and an abnormal electroencephalogram result
whether or not their computed tomography or mag-
netic resonance scan result was normal. For patients
with a non-remote symptomatic seizure and abnormal
electroencephalogram result and computed tomogra-
phyormagneticresonanceimagingscanresulttheesti-
mate was higher than 20% but the lower end of the
confidence interval was less than 20%.
Similarly,althoughthe estimatefromtheunadjusted
resultssuggestedthatpatientswhohadnotstartedanti-
epileptic drug treatment after a single seizure and who
wereseizure-freeforsixmonthshadalessthan20%risk
of recurrence in the next 12 months, our multivariable
resultsindicatedthatsomesubgroupshadarecurrence
risk significantly greater than 20%. This included
patientswithanabnormalelectroencephalogramresult
and abnormal computed tomography or magnetic
resonance scan result whether or not their seizure was
remote symptomatic, and patients with a remote
symptomaticseizureandanabnormalelectroencepha-
logram result whether or not their computed tomogra-
phy result was normal. For some subgroups the
estimate washigher than 20%but the confidence inter-
val included or was less than 20%: patients with a
remote symptomatic seizure and an abnormal electro-
encephalogram result and computed tomography or
magnetic resonance imaging scan result, and patients
with a remote symptomatic seizure and a normal elec-
troencephalogram result and abnormal computed
Table 3 |Effect estimates from univariate and multivariable models
Variables
Univariate P
value
Univariatehazardratio
(95% CI)
Multivariable hazard
ratio (95% CI)
Age at randomisation (years):
16 v 25
0.71
1.00 NA
25 v 35 0.86 (0.59 to 1.23)
35 v 50 1.00 (0.72 to 1.39)
≥50 1.08 (0.79 to 1.48)
Sex:
Men
0.42
1.00 NA
Women 0.90 (0.69 to 1.16)
Cause of seizure:
Not remote symptomatic
0.02*
1.00 1.00
Remote symptomatic 1.45 (1.06 to 1.98)* 1.33 (0.95 to 1.87)
Neurological deficit:
Absent
0.01*
1.00 NA
Present 1.80 (1.17 to 2.76)*
Acute symptomatic seizures:
None
0.96
1.00 NA
Febrile seizures 0.98 (0.55 to 1.75)
Other 1.17 (0.37 to 3.65)
Epilepsy in first degree relative:
No
0.07
1.00 1.00
Yes 1.37 (0.97 to 1.94) 1.33 (0.94 to 1.90)
Seizure type:
Generalised or not definitely focal
0.23
1.00 NA
Partial 0.79 (0.61 to 1.04)
Other 0.83 (0.34 to 2.01)
Seizures only while asleep:
No
0.01*
1.00 1.00
Yes 1.49 (1.11 to 2.00)* 1.47 (1.09 to 1.97)*
EEG results:
Normal
0.00*
1.00 1.00
Abnormal 1.62 (1.25 to 2.09)* 1.55 (1.20 to 2.01)*
Not done or missing 1.48 (0.86 to 2.55)* 1.29 (0.74 to 2.27)*
CT or MRI scan results:
Normal
0.08
1.00 1.00
Abnormal 1.32 (0.91 to 1.91)* 1.07 (0.72 to 1.61)
Not done or missing 1.37 (1.00 to 1.86)* 1.29 (0.94 to 1.78)
Treatment policy:
Delayed
0.13
1.00 1.00
Immediate 0.83 (0.65 to 1.06) 0.82 (0.64 to 1.05)
NA=not applicable; Electroencephalogram=EEG; CT=computed tomography; MRI=magnetic resonance imaging.
*Significant result.
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DISCUSSION
The UK Driving and Vehicle Licensing Agency have
statedthatafterasingleseizuredriverscanregaintheir
ordinary (group 1) licence once they have been free of
seizures for six months provided no risk factors indi-
cateamorethan20%riskofarecurrenceoverthenext
12months.
5Thedecisiontoreducethetimeoffdriving
from 12 to six months, in accordance with recent Eur-
opean Union recommendations, was in part informed
by the data included in this paper. The challenge for
clinicians and the Driving and Vehicle Licensing
Agency is to identify the characteristics of patients
who have a higher than 20% risk of seizure recurrence
in the 12 months after a seizure-free period of six
months. However, currently no published data can
inform decisions as to whether an individual’s risk is
aboveorbelowthis20%threshold.Weestimatedthese
risks using data from the randomised controlled trial,
MESS, assessing the policies of immediate and
deferred drug treatment for epilepsy.
Principal findings
The results of our unadjusted analysis indicated that
the risk of a seizure recurrence in the 12 months after
a seizure-free period of six months was significantly
below 20% for patients who started antiepileptic drug
treatment (risk 14%, 95% confidence interval 10% to
18%). However, multivariable analyses identified sub-
groups whose risk was significantly higher than 20%.
Forpatientswhodidnotstarttreatmenttheunadjusted
estimatewasbelow20%buttheupperlimitofthe con-
fidenceintervalwasgreaterthan20%(risk18%,13%to
23%). Multivariable analyses identified subgroups
with a risk significantly more than 20%. Driving regu-
lators need to decide whether data from unadjusted
analyses or subgroup analyses should be used to
inform decisions. For example, regulators might use
our unadjusted results to justify allowing anyone who
startsantiepilepticdrugtreatmentafterafirstseizureto
drive once they have been seizure-free for six months,
which would be in keeping with the new European
Unionstandards.Alternatively,ourmultivariableana-
lysesmightbeusedtojustifyadecisiontopreventsub-
groups with a higher risk of seizure recurrence from
returning to driving, which is reflected in the current
guidance from the Driving and Vehicle Licensing
Agency.
Strengths and weaknesses of the study
One riskof usinga randomisedcontrolled trialsuch as
MESSistherecruitmentofaselectedpopulationthatis
not necessarily representative of the general popula-
tion, which raises questions about generalisability of
results. In MESS, the baseline characteristics of
patients not randomised were similar to those rando-
mised, which might argue against a major selection
bias when patients made the decision to enter the trial
or not. However, patients were given the opportunity
toenterMESSonlyiftheclinicianwasuncertainabout
the need to start treatment; thus patients entered into
MESSmightnotberepresentativeofthegeneralpopu-
lation of patients presenting with a first seizure. This
might have resulted in people at low risk of a seizure
recurrencenotenteringthetrialastheydidnotwantto
start treatment, and patients at a high risk of a seizure
recurrencenotenteringthe trialastheywantedtostart
treatment. Given the possibility that patients at both
low or high risk of a recurrence did not enter MESS it
isdifficulttopredictwhetherthiswouldhavecausedan
underestimation or overestimation of risks for seizure
recurrenceintheunadjustedanalyses.Inthemultivari-
able analyses, this might have resulted in an overesti-
mationofriskforsubgroupsatlowriskofarecurrence
andanunderestimationofriskforpatientsatahighrisk
of a recurrence.
In MESS, most participants (75%) were randomised
withinthreemonthsof theirfirst seizure.Thusanother
potential selection bias is that some patients had a sec-
ond seizure while waiting to see a specialist and were
thus likely to start treatment at that point rather than
jointhetrial.ThusMESSmighthaverecruitedpatients
with a lower risk of a seizure recurrence than the gen-
eral population. It is unlikely that this has biased ana-
lyses,however,aspatientswitha recurrencewithinsix
monthsof theirfirst seizurecould not contribute to the
risk estimates presented in this paper, as the estimates
were conditional on being seizure-free for six or
12 months after a first seizure. In MESS, participants
were seen predominantly by neurologists experienced
at identifying and classifying seizures, but a further
challenge in outpatient based studies of seizures and
epilepsy, such as MESS, is that seizures are reported
to the clinician by the patient and it is possible that
patients under-report the occurrence of seizures. Vali-
dating patient reporting in an outpatient population
with infrequent seizures is difficult and to date has not
beendone.Ifunder-reportingofseizureshasoccurred,
Table 4 |Risk of seizure recurrence over 12 months at time points after index seizure:
univariate model
Variables
Risk of recurrence at time points (95% CI)
6 months 12 months 18 months
Cause of seizure:
Not remote symptomatic 15 (12 to 19) 8 (5 to 11) 11 (7 to 14)
Remote symptomatic 20 (10 to 30) 13 (4 to 22) 9 (1 to 17)
Neurological deficit:
Absent 15 (12 to 18) 8 (6 to 11) 11 (7 to 14)
Present 31 (13 to 49) 20 (2 to 37) —
Seizures only while asleep:
Yes 19 (11 to 28) 10 (3 to 17) 11 (3 to 19)
No 15 (12 to 19) 9 (6 to 12) 10 (6 to 13)
EEG results:
Normal 13 (9 to 17) 6 (3 to 9) 8 (4 to 12)
Abnormal 19 (14 to 24) 12 (8 to 17) 13 (8 to 18)
Not done or missing* 15 (1 to 29) 10 (0 to 23) —
EEG=electroencephalogram.
*Missing entries arose as a result of insufficient follow-up data or insufficient participant numbers.
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recurrence.
Although we cannot rule out the possibility and
effects of biases from selection and reporting of sei-
zures, MESS remains the largest reported study of
early epilepsy and single seizures. The analysis pre-
sented in this paper allowed an estimation of risks of
seizure recurrence after periods of being seizure-free
and the identification of patients who might be at a
high risk of recurrence.
Comparison with other studies
The National General Practice Study of Epilepsy
15 is
the only other study where risks of recurrence have
been estimated after seizure-free periods. The trial
was a population based study that recruited 564
patients with definite new onset seizures, which
included 446 with unprovoked seizures, 83 with acute
symptomaticseizures,and35withalcoholinducedsei-
zures.Overall,252patientshadasingleseizureastheir
indexseizure,whereastheremainderwereascertained
aftertheirsecondorasubsequentseizure.Whilepopu-
lation based studies might be the ideal design to pro-
duce generalisable estimates of seizure recurrence
risks, the results of the National General Practice
Study of Epilepsy highlight potential problems with
ascertainment in epilepsy studies, particularly where
the outcome of importance is the risk of recurrence
after a first seizure. In their paper assessing recurrence
risks after a first seizure, the National General Practice
Study of Epilepsy group reported analyses for time
from first to second seizure for all patients and for the
subgroup of patients where the index seizure was the
first seizure. Risk estimates of recurrence were signifi-
cantlylowerforthe groupwheretheindex seizurewas
thefirstseizure:37%comparedwith67%at12months.
Survival curves were also given for the risk of a recur-
rence for the whole study population for a seizure-free
periodofsix,12,or18monthsafterafirstseizure.After
sixmonthsofbeingseizure-freetheriskofarecurrence
over the next 12 months was about 35% for the whole
study population, substantially higher than the overall
estimates in our analyses of MESS: 14% with anti-
epileptic drug treatment and 18% without treatment.
For the population in the National General Practice
Study of Epilepsy where the first seizure was the
indexseizure(comparablepopulationinouranalyses),
the riskof a recurrenceover the next 12monthsaftera
seizure-free period of six months was about 18%, simi-
lar to the estimate in our analysis of MESS. This high-
lightstheimportanceofascertainingpatientsaftertheir
first seizure rather than after a second or subsequent
seizure.MultivariableanalysesoftheNationalGeneral
Practice Study of Epilepsy identified symptomatic sei-
zures, neurological deficit, and no antiepileptic drug
treatment as risk factors for a recurrence of seizure
after a first seizure, which were also identified in
MESS. Data from the National General Practice
Study of Epilepsy have not been used to estimate the
risks of recurrence in the next 12 months for patients
seizure-free for various periods for individual risk
groups, and with a fairly small sample size validation
may not be reliable.
Meaning of the study
The unadjusted estimates suggest that after a first sei-
zure, the overall risk of a recurrence in the 12 months
after a seizure-free period of six months is below 20%.
Theconfidenceintervalsaroundestimatessuggestthat
this risk is significantly below 20% for patients who
Table 5 |Risk of seizure recurrence in next 12 months estimated from multivariable model at specific seizure-free periods. Estimates presented assume
seizures not confined to sleep and no first degree relative with epilepsy
Cause of seizure
Test results
Months from
index seizure
Immediate treatment Delayed treatment
EEG CT/MRI
Risk of seizure in next
12 months (%, 95% CI)
Months from index seizure
until annual risk falls <20%
Risk of seizure in next
12 months (%, 95% CI)
Months from index seizure
until annual risk falls <20%
Not remote symptomatic Normal Normal 6 13 (10 to 16)* 1.2 16 (12 to 19)* 3.2
12 7 (5 to 10)* 9 (6 to 12)*
Not remote symptomatic Abnormal Normal 6 20 (16 to 23) 5.5 23 (20 to 26) 7.0
12 11 (9 to 14)* 13 (11 to 16)*
Not remote symptomatic Normal Abnormal 6 14 (11 to 17)* 2.1 17 (14 to 20) 3.6
1 2 8( 5t o1 1 ) * 1 0( 7t o1 2 ) *
Not remote symptomatic Abnormal Abnormal 6 21 (18 to 24) 6.1 25 (22 to 28)† 8.1
12 12 (9 to 15)* 14 (12 to 17)*
Remote symptomatic Normal Normal 6 17 (14 to 20) 3.6 20 (17 to 23) 6.0
12 10 (7 to 12)* 12 (9 to 14)*
Remote symptomatic Abnormal Normal 6 25 (22 to 28)† 8.7 30 (27 to 32)† 10.7
12 15 (12 to 17)* 18 (15 to 20)
Remote symptomatic Normal Abnormal 6 18 (15 to 21) 4.8 22 (19 to 25) 6.5
12 10 (8 to 13)* 13 (10 to 15)*
Remote symptomatic Abnormal Abnormal 6 27 (24 to 30)† 9.2 32 (29 to 34)† 11.3
12 16 (13 to 18)* 19 (16 to 21)
EEG=electroencephalogram; CT=computed tomography; MRI=magnetic resonance imaging.
*Confidence interval lies completely below 20%.
†Confidence interval lies completely above 20%.
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do not. The univariate and multivariable analyses
allow the identification of patients who are at differing
risks of recurrence and hence those who might be at
high or low risk of recurrence at specific time points
after a first seizure. However, guidance is needed
from driving regulators as to how far to individualise
riskandwhethercliniciansshouldfocusonunadjusted
results when making recommendations about driving,
or on results from univariate or multivariable models.
It could be argued that at the population level the risk
(ignoring the confidence interval) of a seizure recur-
rence is below 20% after a six month seizure-free per-
iod; thus all patients should be able to regain their
driving licence, accepting that some in the population
will have a risk above 20%. Alternatively, a more con-
servativeapproachcouldbetakentoindividualiserisk.
The multivariable model identifies several subgroups
that have a risk of recurrence that is significantly
greater than 20% after a six month seizure-free period.
This includes those with a non-remote symptomatic
seizure who do not start treatment and have both an
abnormalelectroencephalogram resultsandanabnor-
mal computed tomography or magnetic resonance
imaging scan result and those with a remote sympto-
matic seizure and an abnormal electroencephalogram
result,irrespectiveoftheresultforcomputedtomogra-
phy or magnetic resonance imaging or treatment pol-
icy. Additionally, the risk estimate for several
subgroups was greater than 20%, although the lower
confidence limit was below 20%. Similarly, the esti-
mate for some subgroups was below 20% but the
upper limit of the confidence interval was above 20%.
Any attemptto utilisethesedata to informdrivingpol-
icycouldhaveimportantimplicationsonresourcesfor
health services, as investigations such as electroence-
phalography may be required that are not otherwise
clinically indicated, and patients could choose to take
antiepileptic drug treatment, which is not otherwise
clinically indicated.
Unanswered questions and future research
Further research and guidance are required to inform
risk basedpolicies, includingregulations aboutreturn-
ing to driving after a single seizure. To inform recom-
mendations about driving, clinicians and patients
require guidance as to whether the focus should be on
risk estimates alone or on risks and their associated
confidence intervals. If the focus is on the estimate
only, our unadjusted estimates suggest that treated
and untreated patients are eligible to drive after being
seizure-free for six months. If the focus is on the risk
estimate and its associated confidence interval, a
patient who starts treatment will be eligible to drive
after being seizure-free for six months. For patients
who do not start treatment the advice depends on the
perspective taken. A conservative approach would
allow patients to regain their licence once the upper
confidence interval has dropped below 20%. This
would prevent patients who do not start treatment
from returning to driving after being seizure-free for
six months, and potentially coerce people into taking
antiepileptic drug treatment that is not otherwise clini-
cally indicated. A more liberal approach would be to
allow people to regain their licence provided that the
lower confidence limit is below 20%. This approach
couldresultinthoseatahighriskofrecurrenceregain-
ing their licence. An intermediate approach might be
torequiretheriskestimatetobebelow20%andalsoto
define the upper limit of the confidence interval that
would be acceptable.
This reanalysis of MESS provides data that can
potentiallyinformdecisionsaboutreturningtodriving
for people who have had a first unprovoked seizure.
MESS recruited a broad heterogeneous population,
which has allowed the investigation of factors that
influence seizure recurrence presented in this paper.
Results should therefore be relevant to the general
population, but selection bias may be at play and
some caution is required in interpreting results. Ide-
ally, external validation of the models presented here
is required and we are in the process of establishing a
consortium to attempt to validate and refine our mod-
els. The MESS data allow an estimation of seizure
recurrence risk conditional on having been seizure-
free for six or 12 months. Further guidance is now
required from driving authorities as to how these data
should be interpreted. In particular, guidance is
needed as to whether a population approach should
betaken,withafocusonunadjustedresultsorwhether
attempts should be made to individualise risk. Gui-
dance is also required as to whether the focus should
be on risk estimates only or on the confidence interval
aswell.Iftheconfidenceintervalistobeincluded,gui-
danceisneededastowhethertheconservative,liberal,
or intermediate approach should be taken.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Peoplewhostarttreatmentafterafirstseizurehavealowerriskofrecurrencethanthosewho
do not
Prognosticmodelshaveshownthatpeoplewithanabnormalelectroencephalogramresultor
neurological deficit have a higher risk of a seizure recurrence
WHAT THIS STUDY ADDS
Six months after an index seizure the overall risk of recurrence in the following 12 months
was significantly below 20% for people who started antiepileptic drug treatment
Seizure while asleep and abnormal electroencephalogram results significantly increase the
risk of a seizure recurrence in the next 12 months according to a multivariable analysis
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